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Maternal cortisol and stress are associated
with birth outcomes, but are not affected
by lipid-based nutrient supplements during
pregnancy: an analysis of data from a
randomized controlled trial in rural Malawi
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David Chaima4, Kenneth Maleta4, Per Ashorn3,5 and Kathryn G. Dewey1
Abstract
Background: Prenatal micronutrient supplements have been found to increase birth weight, but mechanisms for
increased growth are poorly understood. Our hypotheses were that 1) women who receive lipid-based nutrient
supplements (LNS) during pregnancy would have lower mean salivary cortisol concentration at 28 wk and 36 wk
gestation compared to the multiple micronutrient (MMN) and iron-folic acid (IFA) supplement groups and 2) both
salivary cortisol and perceived stress during pregnancy would be associated with shorter duration of gestation and
smaller size at birth.
Methods: Women were enrolled in the trial in early pregnancy and randomized to receive LNS, MMN, or iron-folic
acid (IFA) supplements daily throughout pregnancy. At enrollment, 28 wk and 36 wk gestation, saliva samples were
collected and their cortisol concentration was measured. Self-report of perceived stress was measured using
questionnaires. Gestation duration was indicated by ultrasound dating and newborn anthropometric measurements
(weight, length, head circumference) provided indicators of intrauterine growth.
Results: Of the 1391 women enrolled in the trial, 1372, 906 and 1049 saliva samples were collected from women
at baseline, 28 wk and 36 wk, respectively. There were no significant differences in mean cortisol concentrations by
intervention group at 28 wk or 36 wk gestation. Cortisol concentrations were negatively associated with duration
of gestation (Baseline: β = −0.05, p = 0.039; 36 wk: β = −0.04, p = 0.037) and birth weight (28 wk: β = −0.08, p = 0.035;
36 wk: β = −0.11, p = 0.003) but not associated with length-for-age or head circumference-for-age z-scores. Perceived
stress at 36 wk was significantly associated with shorter newborn LAZ (p = 0.001). There were no significant associations
with the risk of small for gestational age, preterm birth, or low birth weight.
Conclusions: Maternal salivary cortisol concentration was strongly associated with birth weight and duration
of gestation in rural Malawi, but these data do not support the hypothesis that LNS provision to pregnant
women would influence their salivary cortisol concentrations.
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Background
Intrauterine growth restriction and shortened duration
of gestation are risk factors for neonatal morbidity and
mortality [1] and are associated with child growth falter-
ing in many low and middle income country (LMIC) set-
tings [2]. An estimated 15 % of children are born low
birth weight and 11 % are born preterm globally [3].
Complications from preterm birth are estimated to be
responsible for 35 % of the world’s 3.1 million neonatal
deaths [4] and a leading cause of under-5 mortality
worldwide [5]. Risk factors for smaller size at birth or
shortened duration of gestation include poor nutrition
during pregnancy, infections, and maternal stress [6–8].
Interventions to improve birth outcomes in LMIC
have had limited success at increasing size at birth or
duration of gestation. Maternal multiple micronutrient
(MMN) supplements have been found to result in a
small increase in birth weight of 22 g and an increase in
the duration of gestation [9, 10]. Other nutritional inter-
ventions, such as provision of calcium or zinc, have been
found to result in a reduced risk of preeclampsia [11]
and a modest increase in the duration of gestation [12].
Lipid-based nutrient supplements (LNS) provided during
pregnancy have been evaluated for their effects on birth
outcomes and early childhood growth in three studies to
date, in Burkina Faso [13], Ghana [14], Malawi [15].
In impoverished communities, malnutrition is com-
pounded by a variety of physical and psychosocial stressors
that may further compromise pregnancy. Acute or chronic
psychosocial experiences [16] and the biologic measure of
serum or salivary cortisol concentrations [17] have been
associated with shortened duration of gestation and intra-
uterine growth restriction. Cortisol is a regulatory hormone
involved in the hypothalamic-pituitary-adrenal axis (HPA)
response to stress as well as in the fetal-placental-maternal
neuroendocrine system regulating the maintenance of preg-
nancy and the timing of parturition [18]. Cortisol and
corticotropin-releasing hormone (CRH) concentrations rise
exponentially over the course of pregnancy due to a posi-
tive feedback mechanism via the placenta [19]. They peak
at the time of delivery and have been hypothesized to serve
in regulating the ‘placental clock’, determining the timing of
parturition [20]. CRH promotes fetal prostaglandin and
estrogen synthesis, which lead to myometrial activa-
tion and contractility [19]. Cortisol also is involved in
fetal growth and maturation. The late gestation rise
in cortisol concentration is related to a shift from
rapid fetal growth towards tissue maturation [21]. Ele-
vated cortisol concentration is negatively associated
with IGF-1 activity [22] and, importantly, is involved
in fetal lung maturation through the production of
surfactant to prepare the fetus for postnatal life [23].
Despite the physiologic explanations for a normal rise
in cortisol during pregnancy, higher than expected
increases in cortisol and CRH concentrations have
important short- and long-term negative functional
consequences on the health of the pregnancy and the
offspring in later life [24, 25]. In the short term, ele-
vated CRH is associated with placental dysfunction,
including shallow trophoblast invasion and poor pla-
cental vascularization which can lead to intrauterine
growth restriction and preeclampsia [26]. Elevations
in perceived stress and cortisol concentrations have
been related to higher concentrations of proinflammatory
cytokines and lower concentrations of anti-inflammatory
cytokines [27, 28]. In the longer-term, excess glucocortic-
oid exposure has been associated with the life-long func-
tion of the HPA axis in the offspring, and has been
hypothesized to increase susceptibility to a variety of con-
ditions including depression, hypertension, type 2 diabetes
mellitus, and cognitive impairments [25, 29]. The fetus is
somewhat buffered from the effects of high maternal
cortisol concentrations through the activity of the 11-β-
hydroxysteroid dehydrogenase (HSD)-2 enzyme in the
placenta, which converts maternal cortisol to an inactive
cortisone [30]. Yet this is not a perfect barrier and fetal
and maternal cortisol concentrations are highly correlated
suggesting that abnormally high maternal cortisol concen-
trations could affect the developing fetus [31]. The activity
of the 11-β-HSD2 enzyme appears to be sensitive to ma-
ternal malnutrition [24, 32, 33], which would result in
greater fetal exposure to active cortisol, particularly during
late gestation. There is some evidence that cortisol con-
centrations may be elevated among undernourished indi-
viduals, including short term studies suggesting that
cortisol concentration increases during energy restriction
[34, 35] and that stunted children have elevated cortisol
concentrations and a blunted cortisol response to stressors
[36–38]. One trial among Nepali pregnant women re-
ported that late gestation cortisol concentrations were
lower among women who received multiple micronutrient
supplements compared to a control [39], so it is plausible
that improvements in nutrition may alter cortisol concen-
trations. Thus, the effects of malnutrition and elevated
cortisol concentrations during pregnancy may interact
deleteriously on the developing fetus, with both immedi-
ate and long-term results.
In the present study, we aimed to evaluate 1) whether
maternal cortisol concentration would be affected by nu-
tritional supplementation starting early in pregnancy
and 2) whether maternal perceived stress and salivary
cortisol concentration during pregnancy are associated
with smaller newborn size and shorter duration of gesta-
tion. These questions were examined within the context
of a three-armed, randomized controlled trial of LNS,
MMN, or iron-folic acid tablets (IFA) during pregnancy
in rural Malawi. Our hypotheses were that 1) women
who receive LNS during pregnancy would have lower
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salivary cortisol concentration at 28 wk and 36 wk gesta-
tion compared to the MMN and IFA groups and 2) both
salivary cortisol and perceived stress during pregnancy
would be associated with shorter duration of gestation
and smaller size at birth.
Methods
To evaluate these questions, we nested a substudy
within the iLiNS trial in Malawi. Details of the overall
study design methods and primary outcome results have
been published previously [15]. In brief, the target popu-
lation included pregnant women attending antenatal
care through one of four hospitals or health facilities in
Mangochi District in southern Malawi. Inclusion criteria
were as follows: ≤20 wk gestation confirmed by ultra-
sound, residence in the defined catchment area, availability
during the period of the study, and signed or thumb-
printed informed consent. Exclusion criteria were: age
<15 years old, need for medical attention due to a chronic
or severe illness, diagnosed and medically treated asthma,
history of peanut allergy, history of anaphylaxis or serious
allergic reaction to any substance, pregnancy complications
evident at enrolment visit (moderate to severe edema,
blood Hb concentration < 50 g/l, systolic blood pressure
(BP) > 160 mmHg or diastolic BP > 100 mmHg), earlier
participation in the trial during to a previous pregnancy or
concurrent participation in any other clinical trial.
A statistician independent of the research group gen-
erated randomization codes by creating four unique lists
(one for each enrollment site) in blocks of nine (3 codes
for each of the 3 interventions). The codes were inserted
into individual opaque envelopes and eligible partici-
pants selected one from a shuffled stack of 6 envelopes.
This code determined both the participant’s group allo-
cation as well as her identification number.
Based on their randomization code, women received
one of three supplements to be consumed daily through-
out pregnancy: 1) small quantity LNS; 2) MMN; or 3)
IFA. The nutrient content for each of the supplements
can be found in Table 1. Data collectors delivered sup-
plements every two weeks to participants and they
advised women to consume the supplements daily either
after a meal (IFA or MMN groups) or mixed with a meal
(LNS). Data collectors monitored adherence at each dis-
tribution visit by counting any unused supplements from
participants.
At enrollment, trained nurses confirmed pregnancies
and gestational age estimates using ultrasound imagers
(EDAN DUS 3 Digital Ultrasonic Diagnostic Imaging Sys-
tem, EDAN Instruments, Inc., Shekou, Nanshan Shenzhen,
China). Study nurses were trained in ultrasound assess-
ment by two study physicians and they conducted all mea-
surements in duplicate. Anthropometrists measured in
triplicate maternal height using a stadiometer (Harpenden
stadiometer, Holtain Limited, Crosswell, Crymych, UK),
weight using a flat scale (SECA 874 flat scale, Seca GmbH
& Co., Hamburg, Germany), and mid-upper arm circum-
ference (MUAC) using a non-stretchable tape (Weigh and
Measure, LLC, Maryland, USA). Research nurses tested for
malaria using rapid diagnostic tests (Clearview Malaria
Combo, British Biocell International Ltd., Dundee, UK),
haemoglobin concentration (HemoCue AB, Angelholm,
Sweden), and HIV (Alere Determine HIV-1/2, Alere Med-
ical Co., Ltd., Chiba, Japan). Positive HIV tests were re-
peated using another whole blood antibody test (Uni-Gold
HIV, Trinity Biotech plc, Bray, Ireland).
During a follow-up home visit, trained interviewers
asked mothers about demographic and socioeconomic
characteristics, including questions on household food
insecurity. Mothers were asked to return to the clinic for
repeat visits at 32 and 36 wk gestation. A follow-up
home visit was also conducted at 28 wk gestation. At
Table 1 Nutrient content of the supplements
Nutrient IFA MMN LNS
Ration (g/day) 1 tablet 1 tablet 20 g sachet
Total energy (kcal) 0 0 118
Protein (g) 0 0 2.6
Fat (g) 0 0 10
Linoleic acid (g) 0 0 4.59
α-Linolenic acid (g) 0 0 0.59
Vitamin A (μg RE) 0 800 800
Vitamin C (mg) 0 100 100
Vitamin B1 (mg) 0 2.8 2.8
Vitamin B2 (mg) 0 2.8 2.8
Niacin (mg) 0 36 36
Folic acid (μg) 400 400 400
Pantothenic acid (mg) 0 7 7
Vitamin B6 (mg) 0 3.8 3.8
Vitamin B12 (μg) 0 5.2 5.2
Vitamin D (μg) 0 10 10
Vitamin E (mg) 0 20 20
Vitamin K (μg) 0 45 45
Iron (mg) 60 20 20
Zinc (mg) 0 30 30
Copper (mg) 0 4 4
Calcium (mg) 0 0 280
Phosphorus (mg) 0 0 190
Potassium (mg) 0 0 200
Magnesium (mg) 0 0 65
Selenium (μg) 0 130 130
Iodine (μg) 0 250 250
Manganese (mg) 0 2.6 2.6
Stewart et al. BMC Pregnancy and Childbirth  (2015) 15:346 Page 3 of 12
enrolment, 28 wk, and 36 wk gestation, interviewers
asked women about stress during the previous month
using the 10-item Perceived Stress Scale [40], a tool that
has been used in other low-income settings [41, 42].
The research nurses collected saliva samples during the
clinic visits at baseline and 36 wk gestation and during the
28 wk home visit between 8 am and 4 pm after a 30 mi-
nute fast. Time of collection, time of waking, and time of
last food or drink were recorded by the nurse. Saliva col-
lection occurred before any other measurements or sam-
ple collection. Nurses asked each woman to place an inert
polymer cylindrical swab (Salimetrics Oral Swab) under
her tongue for approximately two minutes, while moving
her tongue and jaw as if she were chewing to stimulate
saliva. The woman removed the swab and placed it in a
capped tube and then it was refrigerated or placed on ice
packs. Swabs were brought to room temperature, then
centrifuged for 15 min at 3,000 RPM (1500 x g) to extract
saliva, which then was frozen at −20 °C. After a maximum
of 2 days, samples were transferred to a −80 °C freezer for
longer term storage. Samples were shipped to Davis, CA
for analysis. Lab technicians measured cortisol concentra-
tions in duplicate using an ELISA method (expanded
range high sensitivity salivary cortisol kit, Salimetrics,
State College, PA), which can detect cortisol concen-
trations ranging from 0.193 to 82.77 nmol/L (0.007-
3.0 μg/dL). The intra- and inter-assay coefficient of
variability is 3.5 % and 5.1 %. The mean of each
duplicate measure was used for analysis.
Research nurses collected venous blood samples at
baseline and 36 wk gestation using 7.5 mL trace
mineral-free syringe (Sarstedt Monovette, Nh4-heparin,
Sarstedt Inc., Newton, NC). Lab technicians measured
zinc protoporphyrin in washed red blood cells within
30 hr of collection using a hematofluorometer (Aviv Bio-
medical, Lakewood, NJ). They also measured soluble
transferrin receptor, c-reactive protein (CRP), and alpha-
1-acid glycoprotein (AGP) by immunoturbidimetry on
the Cobas Integra 400 system (F. Hoffmann-La Roche
Ltd, Basel, Switzerland).
Research assistants measured infants’ weight as soon
as possible after birth either at home or in the health
center. Of the recorded birth weights, 89 % were mea-
sured within 48 h of delivery while the remainder were
back-translated from a measurement within 14 days.
They also collected early neonatal measurements, includ-
ing length to the nearest 1 mm using an infantometer
(Harpenden Infantometer, Holtain Limited, Crosswell,
Crymych, UK), weight to the nearest 10 g using an infant
scale (SECA 381 baby scale, Seca GmbH & Co., Hamburg,
Germany), head circumference and arm circumference
using non-stretchable tape.
Women provided written informed consent or indi-
cated their consent to participate in the study with a
thumbprint. In Malawi, individuals ≥15 y are able to
provide consent themselves and so parental consent was
not obtained. The institutional review boards at the
College of Medicine Research and Ethics Committee
(COMREC), University of Malawi and the Ethics Com-
mittee of Pirkanmaa Hospital District, Finland reviewed
and approved the trial protocols at all of the hospitals
and health facilities.
Statistical analysis
Sample size estimates for the main trial were calculated
to be 370 per group, based on an effect size (difference
between groups divided by the pooled SD) of 0.23, as-
suming a two-sided α = 0.05 and β = 0.2. That would cor-
respond to a detectable difference of 0.83 nmol/L in
cortisol and a 1.2 point difference in the perceived stress
score (PSS). We used standard scoring methods to cal-
culate the PSS [40]. We checked the salivary cortisol and
PSS for normality using the Shapiro-Wilk test and corti-
sol was log transformed. We calculated Pearson’s correl-
ation coefficients to compare log cortisol and the PSS at
each time point. We also analyzed PSS and cortisol cat-
egorically. PSS was dichotomized into high or low values
using a median cut-point and cortisol concentrations
were grouped into quartiles based on the distributions at
each measurement point (enrolment, 28 wk, 36 wk).
We used the Household Food Insecurity Access Scale
[43] to estimate food insecurity and created the scores
using standard criteria. An asset index was created using
principal components analysis [44] based on household
ownership of a set of assets (radio, television, cell phone,
bed, mattress, bednet, and bicycle), lighting source,
drinking water supply, sanitation facilities, and flooring
materials.
For all analyses, participants were included if they had
non-missing data on either cortisol or the perceived
stress score at any time-point. We compared character-
istics for those with complete data vs. those who were
missing data on cortisol at 28 wk gestation. We also
compared baseline characteristics between women in
each of the three intervention groups.
To evaluate the effect of the nutritional interventions on
cortisol and PSS, we tested group-wise differences using
ANOVA and ANCOVA models, using the Tukey-Kramer
adjustment for multiple comparisons, and p-values <0.05
were considered statistically significant. We considered
covariates for inclusion in the model if they were signifi-
cantly (p < 0.1) associated with salivary cortisol. These
included baseline cortisol, age, gestational age, maternal
BMI and height, season, malaria infection, HIV status,
hemoglobin, iron status, inflammatory markers, house-
hold food insecurity, asset index, parity (primiparous or
multiparous), infant sex, site of enrollment, and maternal
PSS. We included time since waking and time since last
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meal in all models, regardless of their association with the
outcome variables. Interaction terms were created by the
cross product of the intervention group and maternal age,
parity, baseline BMI, and infant gender and these were
evaluated in linear regression models. Interaction term p-
values <0.1 were considered to be statistically significant.
To examine the associations between cortisol or PSS and
birth outcomes (duration of gestation, weight-for-age z-
score [WAZ], length-for-age z-score [LAZ], head circum-
ference z-score [HCZ]), we used linear regression models
and present standardized regression coefficients. We used
Poisson regression models with robust estimation of the
standard errors to estimate relative risk for dichotomous
birth outcomes, including preterm birth (<37 wk gestation),
low birth weight (<2.5 kg, LBW), stunting (LAZ < −2), small
head circumference (HCZ < −2), and small for gestational
age [45]. We considered covariates for inclusion into the
models based on previous literature and tested as described
above. Because cortisol and the inflammatory markers are
likely related to each other, but the causal pathways are
unclear, we have analyzed models both with and without
adjustment for the two inflammation variables.
Missing data were considered in two ways. We first
compared baseline characteristics between those with
complete data and those with missing data. Secondly,
we imputed missing values [46] for 28 wk and 36 wk
cortisol concentrations and re-analyzed the data as a
sensitivity test on the primary models. Model assump-
tions were also checked using standard regression
diagnostics for linearity, normality, leverage, and in-
fluence. All analyses were performed using SAS 9.3
(SAS Institute, Cary, NC).
Results
Of the total of 1391 women enrolled in the trial, 1372
women had baseline data on cortisol concentration and
PSS. Baseline characteristics of women in the three
intervention groups are shown in Table 2. Women’s ages
ranged from 15 to 49 years and there were no differ-
ences in terms of mean age, education, or other sociode-
mographic factors between groups.
There was some loss to follow-up or missing data on
cortisol or PSS at baseline, 28, and 36 wk gestation
(Fig. 1), but missing data were balanced across the LNS,
MMN, and IFA groups. We compared those with
complete data (n = 883) vs. those with missing data at 28
wk (n = 477 women), the time point with the highest rate
of missing data. We found that women with complete
data were less likely to be anemic (Hb < 110 g/l; 17.0 %
vs. 27.1 %; p < 0.001). Other characteristics, such as age,
baseline cortisol, education, BMI, HIV status, preva-
lence of primiparity, and malaria at enrollment were
generally similar between those in the analytical sam-
ple compared to those with missing data. We re-
peated this comparison for those with missing 36 wk
data (n = 342) and found no significant differences
compared to those with complete data.
Differences by intervention group
Saliva samples were collected at a mean of 12:20 pm,
11:15 am, and 10:30 am at baseline, 28 wk and 36 wk,
respectively. Mean cortisol concentrations at baseline
differed between groups (p = 0.032) with the highest
concentration in the IFA group (6.1 ± 4.7 nmol/L) com-
pared to 5.4 ± 3.0 and 5.5 ± 3.3 nmol/L in the MMN and
LNS groups, respectively (Table 2). Mean PSS at baseline
was 14.4 (±SD: 5.6) and this did not differ by group.
Maternal cortisol values increased during pregnancy,
from 5.7 ± 3.6 nmol/L at baseline to 5.9 ± 3.3 nmol/L at
28 wk and 8.1 ± 3.2 nmol/L at 36 wk gestation (Fig. 2).
PSS did not change substantially during pregnancy and
there was no correlation between maternal perceived
Table 2 Characteristicsa of pregnant women in the ILiNS-DYAD trial in rural Malawi who were included in this analysis
Characteristic IFA MMN LNS p-valueb
Number of participants 413 415 418 n/a
Age, years 25 (6) 25 (6) 25 (6) 0.957
Education, completed years 3.9 (3.4) 4.0 (3.4) 4.1 (3.6) 0.647
Proportion of primiparous women 18.9 % 19.6 % 20.5 % 0.863
Gestational age at enrolment, wk 16.8 (2.1) 16.7 (2.1) 16.9 (2.2) 0.765
Weight, kg 53.8 (7.4) 54.0 (8.2) 54.0 (8.0) 0.962
Body-mass index, BMI (kg/m2) 22.1 (2.6) 22.2 (2.9) 22.1 (2.9) 0.908
Proportion of women with a low BMI (<18.5 kg/m2) 5.3 % 4.4 % 6.3 % 0.530
Proportion of anemic women (Hb < 110 g/l) 17.1 % 18.7 % 19.1 % 0.775
Proportion of women with a positive HIV test 14.8 % 9.9 % 13.1 % 0.145
Proportion with a positive malaria test (RDT) 21.2 % 22.7 % 23.7 % 0.739
aMean (SD) except where noted
bp-value obtained from ANOVA (comparison of means) or Fisher’s exact test (comparison of proportions)
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stress and salivary cortisol at any point during pregnancy
(details not shown). We found no significant group-wise
differences in cortisol in either crude models or those
adjusted for maternal age, education, household asset
index, study site, season, baseline hemoglobin, ZPP, sTfR,
time between waking and saliva collection, and time be-
tween last food or drink and saliva collection (Table 3).
There were also no differences in PSS between groups in
either unadjusted analyses or models adjusted for
maternal age, education (completed years), site of enrol-
ment, season, and household asset index. Interactions
were tested and none was found to be significant.
Associations with birth outcomes
In this sample, the mean birth weight was 2971 (SD 445) g,
birth length was 49.7 (SD 2.2) cm and duration of
gestation was 39.4 (SD 2.1) wk. Salivary cortisol concentra-
tion was associated with a number of birth outcomes in
Fig. 1 Description of sample sizes and missing data at each measurement point among pregnant women in the iLiNS-DYAD trial in Malawi. IFA,
iron-folic acid supplement group; MMN, multiple micronutrient supplement group; LNS, lipid based nutrient supplement group
5
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Fig. 2 Change in salivary cortisol during gestation by intervention group. Data represent mean(SE) cortisol, adjusted for maternal age, education
(completed years), socio-economic status, study site, season, baseline hemoglobin, ZPP, sTfR, time between waking and saliva collection, and time
between last food or drink (besides water) and saliva collection. Measures at 28 wk and 36 wk additionally adjusted for baseline cortisol. MMN, multiple
micronutrient; LNS, lipid-based nutrient supplement; IFA, iron-folic acid supplement
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this study population. Higher cortisol concentration at en-
rolment and 36 wk gestation, but not at 28 wk gestation,
was associated with a shorter duration of gestation in crude
and adjusted models (Table 4). For each SD increase in
baseline log cortisol concentration, there was a reduction
of 0.04 to 0.05 SD in duration of gestation, which translates
to roughly 1 day reduced duration of gestation per SD in-
crease in cortisol. Higher cortisol concentration at 28 wk
and 36 wk gestation was significantly associated with lower
mean birth weight: approximately 40 and 49 g lower per
SD increase in cortisol at those respective time points. At
baseline, cortisol was associated with a lower standardized
birth weight in the multivariate adjusted model (p = 0.013),
but when the model was further adjusted for CRP and
AGP, the point estimate was attenuated and the difference
was no longer statistically significant (p = 0.066). Cortisol
concentration was not found to be associated with new-
born WAZ, LAZ, or HCZ at any time point, however.
There was less of a consistent relationship between PSS
and birth outcomes. Perceived stress at 28 wk and 36 wk
was not associated with duration of gestation but the 36
Table 4 Associations between cortisol at each time point during pregnancy with duration of pregnancy and newborn anthropometric
indicators
Crudea Model 1a,b Model 2a,c
β (95 % CI) p-value β (95 % CI) p-value β (95 % CI) p-value
Duration of pregnancy, wk
Baseline −0.05 (−0.10, 0.01) 0.086 −0.05 (−0.10, −0.01) 0.015 −0.05 (−0.09, −0.002) 0.039
28 wk −0.02 (−0.06, 0.03) 0.528 −0.02 (−0.07, 0.02) 0.305 −0.02 (−0.07, 0.02) 0.343
36 wk −0.05 (−0.08, −0.02) 0.002 −0.04 (−0.07, −0.002) 0.032 −0.04 (−0.07, −0.002) 0.037
Birth weight, g
Baseline −0.08 (−0.14, −0.02) 0.007 −0.08 (−0.14, −0.02) 0.013 −0.06 (−0.12, 0.01) 0.066
28 wk −0.05 (−0.12, 0.02) 0.189 −0.09 (−0.17, −0.02) 0.013 −0.08 (−0.16, −0.01) 0.035
36 wk −0.10 (−0.16, −0.04) 0.0005 −0.11 (−0.18, −0.04) 0.002 −0.11 (−0.18, −0.04) 0.003
Newborn WAZ
Baseline −0.04 (−0.10, 0.02) 0.143 −0.04 (−0.10, 0.03) 0.265 −0.01 (−0.07, 0.05) 0.412
28 wk −0.03 (−0.10, 0.03) 0.328 −0.06 (−0.13, 0.02) 0.129 −0.04 (−0.11, 0.03) 0.319
36 wk −0.05 (−0.11, 0.01) 0.097 −0.05 (−0.12, 0.02) 0.174 −0.04 (−0.11, 0.03) 0.284
Newborn LAZ
Baseline −0.04 (−0.10, 0.02) 0.163 −0.06 (−0.12, 0.01) 0.088 −0.04 (−010, 0.03) 0.255
28 wk −0.04 (−0.11, 0.02) 0.204 −0.06 (−0.13, 0.01) 0.111 −0.04 (−0.12, 0.03) 0.580
36 wk −0.05 (−0.11, 0.01) 0.100 −0.02 (−0.10, 0.05) 0.545 −0.01 (−0.08, 0.06) 0.746
Newborn HCZ
Baseline −0.05 (−0.11, 0.01) 0.095 −0.06 (−0.12, 0.01) 0.089 −0.04 (−0.10, 0.03) 0.273
28 wk −0.05 (−0.12, 0.02) 0.130 −0.07 (−0.14, 0.01) 0.072 −0.06 (−0.13, 0.02) 0.136
36 wk −0.07 (−0.13, −0.01) 0.017 −0.07 (−0.14, 0.01) 0.074 −0.06 (−0.14, 0.01) 0.089
aStandardized regression coefficients, standard errors, and p-values obtained using linear regression models. Data were available for n = 1372, 906, and 1049
women at baseline, 28 wk, and 36 wk, respectively
bAdjusted for parity (primiparous or multiparous), maternal age, sex of fetus, maternal BMI, education, socio-economic score, study site, season at enrolment,
gestational age at enrolment, time between waking and saliva collection, and time between last food or drink (except or water) and saliva collection
cAdjusted for everything in Model 1, plus AGP and CRP
WAZ, weight-for-age z-score; HCZ, head circumference-for-age z-score
Table 3 Mean (SD) cortisol and perceived stress during pregnancy
and birth outcomes by intervention group
Characteristic IFA MMN LNS p-valuea
Cortisol, nmol/L
Baseline 6.0 (4.5) 5.4 (3.2) 5.6 (3.4) 0.032
28 wk 5.7 (2.7) 5.7 (2.8) 6.2 (4.2) 0.280
36 wk 8.4 (3.5) 7.8 (2.7) 8.1 (3.3) 0.080
Perceived stress score
Baseline 14.7 (5.6) 14.2 (5.4) 14.3 (5.4) 0.504
28 wk 14.9 (5.6) 15.2 (6.0) 14.2 (5.8) 0.079
36 wk 13.7 (5.1) 14.0 (5.4) 13.7 (4.9) 0.730
a.p-values represent a test of crude differences between groups using ANOVA
using the Tukey-Kramer adjustment for multiple comparisons. Cortisol models
at 28 wks and 36 wk were additionally tested in a model adjusting for baseline
cortisol. Adjusted means did not differ from crude values and p-values were
0.14 at 28 wk and 0.24 at 36 wk
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wk measure was significantly associated with shorter
newborn LAZ (p = 0.001). No other associations were
significant.
We also examined the association between cortisol
categorized into quartiles and dichotomous birth out-
comes (Table 5). Here we found that those with cortisol
in the uppermost quartile experienced a 56 % higher risk
of newborn stunting compared to those in the lowest
quartile (RR: 1.56; 95 % CI 1.08 to 2.25) in a multivariate
adjusted model. However, when further adjusted for
CRP and AGP, the effect size was attenuated (RR: 1.42;
95 % CI 0.96 to 2.09) and the difference was no longer
statistically significant (p = 0.076). There was a relatively
consistent association between higher cortisol at 28 wk
or 36 wk gestation and an increased risk of LBW. Those
with a cortisol concentration in Q3 or Q4 had a roughly
2-fold increased risk of LBW compared to those in the
lowest quartile. Cortisol concentration was not signifi-
cantly associated with SGA in adjusted models. Finally,
we also examined the association between PSS dichoto-
mized into high vs. low using a median value cutoff.
High PSS at 36 wk gestation was associated with a 71 %
higher risk of newborn stunting (RR: 1.71; 1.22 to 2.41;
p = 0.002), but was not significantly associated with the
other birth outcomes (data not shown).
Interactions were tested and found to be statistically
significant for parity (p = 0.034). Among multiparous
women, there was no difference in birth weight with in-
creasing cortisol concentration; however, among prim-
iparous women, cortisol concentrations in the 3rd or 4th
quartile were associated with lower mean WAZ at birth
(Fig. 3). No other tested interactions were found to be
statistically significant.
Evaluation of missing data and sensitivity analyses
Using multiple imputation to estimate missing cortisol data
at 28 wk and 36 wk, we re-analyzed the data and found,
consistent with the primary analyses, there were no signifi-
cant differences in cortisol concentration by intervention
group. All coefficients in the imputed models were within
10 % of the values in the limited models (data not shown).
Discussion
The present study tested the hypothesis that the
provision of LNS would alter maternal salivary cortisol
concentrations during gestation, and evaluated the asso-
ciations between biologic markers of stress response or
perceived stress during pregnancy and birth outcomes.
Our results did not support the primary study hypoth-
esis; we observed no association between LNS exposure
and cortisol concentrations during mid- to late gestation
and so we conclude that there was no effect of the inter-
vention. In this study population, cortisol concentration
at varying points during gestation was associated with
duration of gestation, birth weight, and risk of LBW, but
not risk of SGA. We also found that a woman’s report of
perceived stress in the past month was associated with a
modest increase in the risk of newborn stunting.
Our intervention effect results are similar to recent re-
sults from a trial in Ghana and two trials in Burkina
Faso [47, 48], but differ from those of a study in Nepal
[49]. In the Ghana study, in which women had a
mean BMI of ~27 kg/m2 and 45 % were between 18–25 y,
salivary cortisol concentrations did not differ between
intervention groups overall. However, there was evidence
of an interaction with maternal age whereby maternal cor-
tisol concentrations were 1.06 nmol/L lower among youn-
ger women (<25 y) in the LNS group compared to
similarly aged women in the IFA control group [50]. This
difference was not observed among older women, nor was
there evidence of a difference between the MMN and the
IFA groups in either of the age categories. In Burkina Faso,
cord blood cortisol concentrations did not differ between
groups in either a trial of MMN [48] or a trial of LNS [47]
during pregnancy. However, there was a significant inter-
action between parity and MMN supplementation, such
that cord blood cortisol concentrations were higher
among primiparous women in the MMN group compared
to the controls (IFA), a finding not apparent among mul-
tiparous women. In the Nepal study, in which women had
a mean BMI of ~19 kg/m2 and approximately 30 % were
<19 y, maternal serum cortisol concentrations were mar-
ginally lower by 1.32 μg/dL (p = 0.062) in the MMN group
relative to the vitamin A control group [39]. In the present
study, women were similar in age (mean of 25 y) to those
in the Ghana and Burkina Faso studies, but had lower
mean BMI (22 kg/m2).
There are a number of possible explanations for why
there was no impact of the supplements on maternal cor-
tisol concentrations in this study but some apparent dif-
ferences between groups in the other four trials, either in
main or subgroup analyses. First, it is possible that nutri-
ent deficiencies may not have been severe enough in our
study setting to serve as a trigger for elevated maternal
cortisol concentration as was seen in the Nepal trial.
Maternal underweight was relatively uncommon in the
Malawi study population, where only 5 % of women had
low BMI (<18.5 kg/m2) at enrollment during early preg-
nancy. An alternative explanation is that the nutrients
provided by LNS or MMN were insufficient to alter ma-
ternal cortisol concentrations. In this trial, there was no
overall significant effect of LNS or MMN on duration of
gestation or newborn anthropometric indicators [15],
although the small increases in birth weight of ~50 g are
in concordance with other trials of multiple micronutri-
ents or LNS interventions during pregnancy [9, 13]. Both
the Ghana and Nepal study sites reported significant
increases in birth weight [14, 49]. A third potential
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Table 5 Risk of adverse birth outcomes in participants by quartile of cortisol concentrations during pregnancy
Crude Adjusteda
Quartile Cases (%) RR (95 % CI) p-valueb RR (95 % CI) p-valueb
Preterm birth (<37 wk)
Baseline 1 29 (8.3) 1 0.258 1 0.384
2 34 (10.5) 1.26 (0.79 to 2.02) 1.31 (0.75 to 2.31)
3 35 (11.2) 1.34 (0.84 to 2.14) 1.22 (0.68 to 2.21)
4 30 (10.8) 1.30 (0.80 to 2.12) 1.29 (0.76 to 2.20)
28 wk 1 20 (8.6) 1 0.753 1 0.833
2 18 (8.9) 1.03 (0.56 to 1.90) 0.92 (0.45 to 1.87)
3 15 (7.0) 0.81 (0.43 to 1.54) 0.50 (0.26 to 0.99)
4 24 (10.0) 1.16 (0.66 to 2.05) 1.00 (0.49 to 2.04)
36 wk 1 2 (0.7) 1 0.092 – –
2 9 (3.3) 4.75 (1.03 to 21.77)
3 6 (2.7) 3.90 (0.80 to 19.15)
4 8 (3.2) 4.64 (0.99 to 21.65)
Small for gestational age
Baseline 1 77 (28.0) 1 0.428 1 0.246
2 81 (31.3) 1.13 (0.87 to 1.47) 1.08 (0.81 to 1.44)
3 83 (34.0) 1.22 (0.94 to 1.58) 1.17 (0.88 to 1.55)
4 68 (30.2) 1.09 (0.82 to 1.43) 1.14 (0.85 to 1.53)
28 wk 1 53 (28.3) 1 0.5332 1 0.258
2 37 (24.0) 0.85 (0.59 to 1.22) 0.88 (0.59 to 1.32)
3 58 (31.0) 1.09 (0.80 to 1.50) 1.23 (0.88 to 1.71)
4 56 (29.3) 1.04 (0.76 to 1.43) 1.11 (0.79 to 1.56)
36 wk 1 61 (24.4) 1 0.028 1 0.121
2 71 (31.4) 1.29 (0.96 to 1.72) 1.41 (1.01 to 1.98)
3 68 (35.4) 1.45 (1.09 to 1.94) 1.39 (0.97 to 1.97)
4 67 (32.8) 1.34 (1.00 to 1.80) 1.28 (0.90 to 1.81)
Low birth weight (<2500 g)
Baseline 1 35 (11.4) 1 0.111 1 0.170
2 37 (12.6) 1.10 (0.72 to 1.70) 1.00 (0.64 to 1.55)
3 38 (13.8) 1.21 (0.79 to 1.86) 1.01 (0.63 to 1.61)
4 40 (15.9) 1.39 (0.91 to 2.12) 1.31 (0.85 to 2.02)
28 wk 1 16 (7.7) 1 0.002 1 0.001
2 15 (8.2) 1.05 (0.54 to 2.07) 1.13 (0.55 to 2.55)
3 30 (14.6) 1.88 (1.06 to 3.35) 2.01 (1.08 to 3.74)
4 35 (16.2) 2.10 (1.20 to 3.67) 2.56 (1.31 to 5.00)
36 wk 1 15 (5.5) 1 0.003 1 0.027
2 23 (9.1) 1.66 (0.89 to 3.11) 2.54 (1.15 to 5.59)
3 36 (16.7) 3.03 (1.71 to 5.39) 3.15 (1.46 to 6.78)
4 27 (11.7) 2.13 (1.16 to 3.90) 2.14 (1.01 to 4.56)
Newborn stunting (HAZ < −2)
Baseline 1 45 (15.3) 1 0.099 1 0.072
2 42 (15.0) 0.98 (0.67 to 1.44) 1.17 (0.80 to 1.72)
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explanation is that elevations in maternal cortisol concen-
tration in this context were due to other non-nutritional
physical or psychosocial stressors. The HPA axis is
activated during infection and cortisol has important im-
munomodulatory effects [51], so elevated cortisol concen-
tration may have been more strongly associated with an
infectious disease burden rather than malnutrition. Corti-
sol response to stressors is generally blunted during preg-
nancy [52], which is in line with our finding of no
correlation between the PSS and cortisol in this cohort.
We found that there were strong associations between
maternal cortisol concentrations at some time points
during pregnancy and birth weight or duration of gesta-
tion, and that the association with birth weight was
strongest among primiparous women. Associations were
attenuated with adjustment for CRP and AGP, which
suggests that infection or inflammation were related to
this relationship, either as confounding or mediating
factors. There was no association with the risk of SGA,
which suggests that the observed differences in birth
weight were likely due to the earlier timing of birth,
rather than due to intrauterine growth restriction. Late
gestation perceived stress was also associated with lower
newborn length. These findings are consistent with a
number of other studies, including the Ghanaian and
Nepali trials described above. Numerous studies have
reported an association between maternal cortisol or
psychosocial stress during pregnancy and adverse birth
outcomes, primarily shorter duration of gestation, the
descriptions of which can be found in a number of well-
written reviews [16, 17]. Our findings differ somewhat
from the Burkinabe trial, which measured cord blood
cortisol concentrations and found there to be no associ-
ation with measures of size at birth [48]. A possible
explanation for this apparent difference may reflect the
different pools from which the cortisol was measured
and timing of measurement. We measured maternal
salivary cortisol concentrations during gestation, while
Roberfroid et al. measured cord serum concentrations.
While maternal and fetal cortisol concentrations are
correlated, they may act on fetal growth and timing of
parturition through different pathways.
Strengths of the present study include the large pro-
spective design with multiple measures during pregnancy
and generally high rates of follow-up. Imputation of miss-
ing data did not substantially change the interpretation of
the main findings. The randomized controlled trial design
reduced the potential for confounding and bias in the
analysis of the effects of the maternal supplements and
cortisol concentrations during pregnancy. Unfortunately,
resource constraints limited our ability to measure CRH
and logistical constraints in the field limited our ability to
highly control the timing and sampling protocols for saliv-
ary cortisol. Cortisol follows a strong diurnal pattern and
Fig. 3 Interaction between baseline cortisol and parity on newborn
weight-for-age z-score. Data represent mean (SE) weight for age
z-score. P-value for interaction = 0.034
Table 5 Risk of adverse birth outcomes in participants by quartile of cortisol concentrations during pregnancy (Continued)
3 41 (15.3) 1.00 (0.68 to 1.48) 1.02 (0.68 to 1.52)
4 48 (21.3) 1.39 (0.96 to 2.01) 1.56 (1.08 to 2.25)
28 wk 1 25 (12.1) 1 0.095 1 0.309
2 27 (15.1) 1.25 (0.75 to 2.07) 1.24 (0.73 to 2.10)
3 33 (16.8) 1.39 (0.86 to 2.25) 1.49 (0.89 to 2.51)
4 37 (17.9) 1.47 (0.92 to 2.36) 1.16 (0.72 to 1.87)
36 wk 1 29 (10.9) 1 0.195 1 0.281
2 38 (15.2) 1.38 (0.88 to 2.16) 1.69 (1.03 to 2.77)
3 30 (14.6) 1.34 (0.83 to 2.16) 1.47 (0.86 to 2.53)
4 33 (15.2) 1.39 (0.88 to 2.22) 1.29 (0.74 to 2.23)
aAdjusted for parity (primiparous or multiparous), maternal age, sex of fetus, maternal BMI, education, socio-economic score, study site, season at enrolment,
gestational age at enrolment, time between waking and saliva collection, and time between last food or drink (except water) and saliva collection, and
gestational age at enrolment
bp-value for trend obtained from Poisson regression models
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is responsive to recent events. While we attempted to con-
trol for this by standardizing the timing of the sample col-
lection during the course of the clinic visit, we were not
able to control the timing of arrival of the participants.
Thus, the samples were collected throughout the day and
we adjusted for time since waking and time since last meal
in all of our analyses. Ideally, one would collect multiple
samples at standardized times over the course of the day
and/or before and after an HPA challenge [53]; however,
this was not feasible in this context. Because this measure-
ment error was likely non-differential with regard to birth
outcomes, the effect size estimates may be biased towards
the null and, therefore, are a conservative estimate of the
true magnitude of the association between cortisol and
birth outcomes. This is supported by the consistency
between our study and others on this topic. On the other
hand, non-differential measurement error could have
masked any true association between the supplement
interventions and cortisol concentrations.
Conclusions
We did not observe an effect of maternal supplementa-
tion with LNS or MMN on cortisol concentrations in
late gestation among Malawian women. Nevertheless,
we found that maternal cortisol concentrations were
strongly associated with newborn anthropometric mea-
surements and duration of gestation, reiterating findings
from studies in other populations regarding the import-
ance of this hormone for pregnancy outcomes.
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